<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251910</url>
  </required_header>
  <id_info>
    <org_study_id>BXCL501-103</org_study_id>
    <nct_id>NCT04251910</nct_id>
  </id_info>
  <brief_title>Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia</brief_title>
  <acronym>TRANQUILITY</acronym>
  <official_title>A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioXcel Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioXcel Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind,&#xD;
      placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics,&#xD;
      safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females&#xD;
      with acute agitation associated with dementia. Evaluation of 3 doses are planned.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2 randomized, double-blind, placebo controlled, ascending dose finding&#xD;
      study assessing efficacy, pharmacokinetics, safety, and tolerability of BXCL501 with 3 dosing&#xD;
      groups in adult (65 years and older) males and females with acute agitation associated with&#xD;
      all forms of dementia. Evaluation of three (3) doses of sublingual BXCL 501 are planned.&#xD;
      Cohort 1, Cohort 2 and Cohort 3 will be given 30µg, 60µg and 90µg dose respectively of&#xD;
      BXCL501 or placebo. Subjects assigned to Cohort 3 will participate in a 1-week safety&#xD;
      observation before being enrolled.&#xD;
&#xD;
      This is an adaptive design as doses selected for testing may be different from these, based&#xD;
      upon safety reviews. Doses lower or higher may be chosen to test, up to 180µg, and additional&#xD;
      subjects may be added to a cohort. BXCL501 films may be divided in half if needed to deliver&#xD;
      half-dose strengths. At least 30 subjects (10 per cohort) will be enrolled at up to 3 study&#xD;
      sites in the United States. In Part B a total of 46 subjects will receive BXCL501 40 μg or&#xD;
      matching placebo film.&#xD;
&#xD;
      The effects of BXCL 501 on acute agitation will be assessed by the following scales:&#xD;
      Pittsburgh Agitation Scale (PAS), the PANSS-EC (PEC), Cohen-Mansfield Agitation Inventory&#xD;
      (CMAI), CGI-Severity for Agitation and CGI Improvement for Agitation. Adverse Events (AEs),&#xD;
      clinical laboratory tests, ECG, and vital signs will be monitored, and all observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) This is a double-blind study. Due to the nature of the drug, the pharmacist and the drug administrator will both be aware of the treatment. They have no other responsibility in the trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal laboratory test results</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of abnormal laboratory test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal vital signs</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of abnormal vital sign (systolic and diastolic blood pressures, heart rate measured as pulse, respiratory rate, and temperature)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal ECG findings</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of abnormal ECG findings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of calming effects</measure>
    <time_frame>24 hours</time_frame>
    <description>Magnitude of calming effects of different doses of BXCL501 on symptoms of acute agitation associated with dementia as measured by the Pittsburgh Agitation Scale (PAS) (Minimum Score value: 0. Maximum score value 16. higher scores mean a worse outcome).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Agitation,Psychomotor</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Cohort 1- 30 Micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2- 60 Micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo.&#xD;
Additional 20 subjects receive 60 Micrograms or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3- 90 Micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part B cohort consists 46 subjects receiving 40 Micrograms or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual film containing Dexmedetomidine</intervention_name>
    <description>Sublingual film containing Dexmedetomidine</description>
    <arm_group_label>Cohort 1- 30 Micrograms</arm_group_label>
    <arm_group_label>Cohort 2- 60 Micrograms</arm_group_label>
    <arm_group_label>Cohort 3- 90 Micrograms</arm_group_label>
    <arm_group_label>Part B Cohort</arm_group_label>
    <other_name>BXCL501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual Placebo Film</intervention_name>
    <description>Sublingual placebo film that matches BXCL501</description>
    <arm_group_label>Cohort 1- 30 Micrograms</arm_group_label>
    <arm_group_label>Cohort 2- 60 Micrograms</arm_group_label>
    <arm_group_label>Cohort 3- 90 Micrograms</arm_group_label>
    <arm_group_label>Part B Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients 65 years and older.&#xD;
&#xD;
          -  Patients who have dementia and a history of acute agitation.&#xD;
&#xD;
          -  History of agitation that requires intervention or impairs social or daily activities&#xD;
&#xD;
          -  Patients who meet International Psychogeriatric Association (IPA) diagnostic criterion&#xD;
             for agitation.&#xD;
&#xD;
          -  Patients with a total score of ≥ 8 on the Pittsburgh Agitation Scale (PAS).&#xD;
&#xD;
          -  Patients who have a score of ≥ 2 on at least 1 of the 4 items on the Pittsburgh&#xD;
             Agitation Scale (PAS).&#xD;
&#xD;
          -  Patients who read, understand and provide written informed consent, or who have a&#xD;
             Legally Authorized Representative (LAR).&#xD;
&#xD;
          -  Patients who are in good general health.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For Part B: Patients with dementia associated with Parkinson's disease and/or Lewy&#xD;
             Body Disease, if etiology of dementia is known.&#xD;
&#xD;
          -  Patients with agitation caused by acute intoxication.&#xD;
&#xD;
          -  Patients treated within 4 hours prior to study drug administration with&#xD;
             benzodiazepines, other sedatives, hypnotics or oral or short-acting intramuscular&#xD;
             antipsychotics must be excluded.&#xD;
&#xD;
          -  Treatment with alpha-1 noradrenergic blockers, alpha adrenergic antagonists within 8&#xD;
             hours prior to dosing.&#xD;
&#xD;
          -  No new chronic medications initiated in the past 14 days prior to screening excluding&#xD;
             over-the-counter products taken sporadically.&#xD;
&#xD;
          -  Patients at significant risk of harm to themselves or others&#xD;
&#xD;
          -  Patients considered medically unstable or in recovery&#xD;
&#xD;
          -  Patients with history of clinically significant syncope or syncopal attacks,&#xD;
             orthostatic hypotension within the past 2 years, current evidence of hypovolemia,&#xD;
             orthostatic hypotension.&#xD;
&#xD;
          -  Cohort 3 only: Patients who are taking nitrates or beta blockers shall be excluded.&#xD;
             Any other anti-hypertensives should be maintained in the course of the study.&#xD;
&#xD;
          -  Patients who have received an investigational drug within 30 days prior to the current&#xD;
             agitation episode must be excluded.&#xD;
&#xD;
          -  Patients experiencing clinically significant pain, per Investigator.&#xD;
&#xD;
          -  Cohort 3 only: Patients who are a high fall risk assessed via the Johns Hopkins Fall&#xD;
             Risk Assessment (total score &gt;13) or during the 1-week safety observation period&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Hemsen</last_name>
    <phone>475-254-5899</phone>
    <email>Lhemsen@bioxceltherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cedric Burg</last_name>
    <email>cburg@bioxceltherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bioxcel CTM</last_name>
      <phone>475-254-5899</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-254-5899</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BioXcel CTM</last_name>
      <phone>475-254-5899</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bioxcel CTM</last_name>
      <phone>475-254-5899</phone>
      <email>info@bioxceltherapeutics.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

